The launch of combination products for the treatment of urinary tract infections is an emerging trend in the genito-urinary disorder drugs market. Competitors in the market are developing combination drugs to fight multi-drug resistant bacteria and also expanding indications for existing drugs for the treatment of genito-urinary disorders. For instance, Merck Sharp & Dohme Corp. offers ZERBAXA, a combination drug of a novel cephalosporin and a beta-lactamase inhibitor used for the treatment of complicated urinary tract infections.
THE BUSINESS RESEARCH COMPANY EXPECTS THE GLOBAL GENITO-URINARY DRUGS MARKET TO GROW TO $82 BILLION BY 2021
North America was the largest region in the genito-urinary drugs market in 2017, accounting for less than two-fifth of the market share. This can be attributed to the robust healthcare infrastructure, awareness and technological advancements in manufacturing of genitourinary drugs. Moreover, the prevalence of urinary diseases like chronic kidney diseases (14% of the US population), women infertility (12% of US population) etc. is high. Over the past 10 years, erectile dysfunction has almost doubled due to the increased prevalence of obesity and diabetes which is contributing to the size of this market.
The chart below shows the year-on-year growth of the global genito-urinary drugs market during 2017 – 2021
According to The Business Research Company’s Consultant, Nitin Gianchandani, the genito-urinary drugs market witnessed increased mergers and acquisition activity in the past few years. Companies in the genito-urinary drugs market are acquiring their competitors to expand geographically and for the research and development of new products. In November 2014, AstraZeneca collaborated with Cancer Research UK for the screening of cancer medicine. In December 2014, Pfizer merged with Wyeth to become one of the top ten drug companies in India by market share.
Download a sample of the report at:
Daiichi Sankyo Company, Limited was the largest competitor with 4.2% of the market, generating revenues of $2.6 billion for the financial year 2016. Daiichi Sankyo Company’s growth strategy aims to expand operations and strengthen product portfolio. The company plans to significantly invest in its locations in New York and Ohio to increase capacity and flexibility to respond to critical market needs. In China, the company is achieving coverage by allying with local partners in certain areas. It has also adopted new product development techniques such as cell therapy.
The genitourinary drugs market covers drugs that are used in the treatment of diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, Reno vascular diseases, benign prostate diseases, and other related diseases.
Genito-Urinary Drugs Global Market Report 2018 is a detailed report giving a unique insight into this market. The report is priced at $4000 for an individual user. To use across your office, the price is $6000 and $8000 if you wish to use across a multinational company.
About The Business Research Company:
Visit TheBusinessResearchCompany.com, mail [email protected] or call +447443439350 or +918897263534 or +919160996838 for more information on this and many other titles.
The Business Research Company is a market research and intelligence company, which excels in company, market and consumer research.
It has research professionals at its offices in the UK, India and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, chemicals and technology.
The Business Research Company’s management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world’s largest organizations.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: [email protected]